10:25 AM EDT, 09/26/2024 (MT Newswires) -- EnGene Holdings ( ENGN ) said Thursday preliminary results from the pivotal cohort of an ongoing study demonstrated a 71% complete response rate at any time for its investigational product detalimogene voraplasmid in patients with BCG-unresponsive non-muscle invasive bladder cancer.

The complete response rate was 67% at three months and 47% at six months, the company said, adding there were no drug-related discontinuations of treatment.

Of the 42 patients evaluated for safety, two developed peripheral edema and urosepsis, considered grade 3 treatment-related adverse events, while 20 reported at least one mild to moderate adverse events, the company said.

Shares of the company fell 20% in recent trading.

Price: 5.00, Change: -1.25, Percent Change: -20.00